<rss version="2.0">
<channel>
<title>IBTimes.com RSS Feed - APPX</title>
<description>International Business News - APPX</description>
<link>http://www.ibtimes.com</link>
<copyright>All articles are copyrighted by IBTimes.com</copyright>

<image>
	<title>The International Business Times - Business News, Updated daily</title> 
	<width>400</width> 
	<height>100</height> 
	<link>http://www.ibtimes.com/</link> 
	<url>http://www.ibtimes.com/images/top_logo_ibt2_3.gif</url> 
</image>


  <item>
  <title>US regulators approve Fresenius buyout of APP</title>
  <description>APP Pharmaceuticals Inc. said Tuesday U.S. regulators have cleared the way for its purchase by German dialysis-clinic operator Fresenius. In July, Hamburg-based Fresenius announced its plan to purchase APP for $3.7 billion in cash, or $23 per share, plus potential contingent payments of $970 million, or $6 per share. APP said Tuesday it expects the deal to close by mid-September, now that the Federal Trade Commission has completed its review of the transaction. German authorities previously signed off on the deal.</description>
    <link>http://www.ibtimes.com/articles/20080902/us-regulators-approve-fresenius-buyout-of-app.htm</link> 
  <pubDate>Tue, 02 Sep 2008 14:29:17 EDT</pubDate>
  </item>


  <item>
  <title>US regulators approve Fresenius buyout of APP</title>
  <description>APP Pharmaceuticals Inc. said Tuesday U.S. regulators have cleared the way for its purchase by German dialysis-clinic operator Fresenius. In July, Hamburg-based Fresenius announced its plan to purchase APP for $3.7 billion in cash, or $23 per share, plus potential contingent payments of $970 million, or $6 per share. APP said Tuesday it expects the deal to close by mid-September, now that the Federal Trade Commission has completed its review of the transaction. German authorities previously signed off on the deal.</description>
    <link>http://www.ibtimes.com/articles/20080902/us-regulators-approve-fresenius-buyout-of-app.htm</link> 
  <pubDate>Tue, 02 Sep 2008 13:10:30 EDT</pubDate>
  </item>


  <item>
  <title>GE, GM, Yahoo, APP Pharma among big movers</title>
  <description>Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and Nasdaq Stock Market: NYSE</description>
    <link>http://www.ibtimes.com/articles/20080707/ge-gm-yahoo-app-pharma-among-big-movers.htm</link> 
  <pubDate>Mon, 07 Jul 2008 17:22:47 EDT</pubDate>
  </item>


  <item>
  <title>APP Pharmaceuticals shares jump on buyout offer</title>
  <description>Shares of drug developer APP Pharmaceuticals Inc. soared Monday after German health care company Fresenius SE offered a cash buyout of $3.7 billion, or $23 per share.</description>
    <link>http://www.ibtimes.com/articles/20080707/app-pharmaceuticals-shares-jump-on-buyout-offer.htm</link> 
  <pubDate>Mon, 07 Jul 2008 11:50:39 EDT</pubDate>
  </item>


  <item>
  <title>Out of the Gate: APP Pharmaceuticals shares spike</title>
  <description>Shares of APP Pharmaceuticals Inc. skyrocketed Monday after Germany's Fresenius SE said it will buy the U.S. generic drug maker for $3.7 billion in cash.</description>
    <link>http://www.ibtimes.com/articles/20080707/out-of-the-gate-app-pharmaceuticals-shares-spike.htm</link> 
  <pubDate>Mon, 07 Jul 2008 09:46:33 EDT</pubDate>
  </item>


  <item>
  <title>Premarket Movers: Pharma stocks lead mixed session</title>
  <description>Pharmaceutical shares were front and center in premarket trading Monday as U.S. markets appeared headed for a mixed open following the holiday weekend.</description>
    <link>http://www.ibtimes.com/articles/20080707/premarket-movers-pharma-stocks-lead-mixed-session.htm</link> 
  <pubDate>Mon, 07 Jul 2008 08:53:05 EDT</pubDate>
  </item>


  <item>
  <title>Fresenius paying $3.7B for US drugmaker APP</title>
  <description>Fresenius SE said Monday it has agreed to buy U.S. generic drug maker APP Pharmaceuticals for $3.7 billion in cash in a deal that will give the German health care company more opportunities in the North American market for drugs administered intravenously.</description>
    <link>http://www.ibtimes.com/articles/20080707/fresenius-paying-3-7b-for-us-drugmaker-app.htm</link> 
  <pubDate>Mon, 07 Jul 2008 17:24:16 EDT</pubDate>
  </item>


  <item>
  <title>FDA OKs APP Pharma's generic nausea injection</title>
  <description>APP Pharmaceuticals Inc. said Thursday it received final approval from the Food and Drug Administration to market its granisetron hydrochloride injection, the generic version of Hoffmann-LaRoche's Kytril injection for chemo-induced nausea.</description>
    <link>http://www.ibtimes.com/articles/20080703/fda-oks-app-pharmas-generic-nausea-injection.htm</link> 
  <pubDate>Thu, 03 Jul 2008 08:13:54 EDT</pubDate>
  </item>


  <item>
  <title>APP Pharmaceuticals 1Q profit falls on interest expense</title>
  <description>APP Pharmaceuticals Inc., which makes injectable products for acute medical care, said Thursday its first-quarter profit fell 18 percent, hurt by higher interest expenses.</description>
    <link>http://www.ibtimes.com/articles/20080508/app-pharmaceuticals-1q-profit-falls-on-interest-expense.htm</link> 
  <pubDate>Thu, 08 May 2008 10:12:23 EDT</pubDate>
  </item>


  <item>
  <title>APP Pharmaceuticals names new CEO, chief financial officer</title>
  <description>Injection maker APP Pharmaceuticals Inc. said Thursday it named Thomas H. Silberg as president and chief executive, succeeding Patrick Soon-Shoing, who will remain chairman.</description>
    <link>http://www.ibtimes.com/articles/20080501/app-pharmaceuticals-names-new-ceo-chief-financial-officer.htm</link> 
  <pubDate>Thu, 01 May 2008 08:19:44 EDT</pubDate>
  </item>


</channel>
</rss>